309 related articles for article (PubMed ID: 16652380)
41. Preference, compliance and initial outcome of therapeutic options chosen by female patients with urinary incontinence.
Diokno A; Yuhico M
J Urol; 1995 Nov; 154(5):1727-30; discussion 1731. PubMed ID: 7563333
[TBL] [Abstract][Full Text] [Related]
42. A multicenter, prospective, randomized clinical trial comparing tension-free vaginal tape surgery and no treatment for the management of stress urinary incontinence in elderly women.
Campeau L; Tu LM; Lemieux MC; Naud A; Karsenty G; Schick E; Corcos J
Neurourol Urodyn; 2007; 26(7):990-4. PubMed ID: 17638307
[TBL] [Abstract][Full Text] [Related]
43. Reliability and convergent and discriminant validity of the Child Oral Health Impact Profile (COHIP Child's version).
Broder HL; Wilson-Genderson M
Community Dent Oral Epidemiol; 2007 Aug; 35 Suppl 1():20-31. PubMed ID: 17615047
[TBL] [Abstract][Full Text] [Related]
44. Age-specific prevalence of, and factors associated with, different types of urinary incontinence in community-dwelling Australian women assessed with a validated questionnaire.
Botlero R; Davis SR; Urquhart DM; Shortreed S; Bell RJ
Maturitas; 2009 Feb; 62(2):134-9. PubMed ID: 19181467
[TBL] [Abstract][Full Text] [Related]
45. Transobturator tape for treatment of female stress urinary incontinence: objective and subjective results after a mean follow-up of two years.
Giberti C; Gallo F; Cortese P; Schenone M
Urology; 2007 Apr; 69(4):703-7. PubMed ID: 17445655
[TBL] [Abstract][Full Text] [Related]
46. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
47. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder.
Colman S; Chapple C; Nitti V; Haag-Molkenteller C; Hastedt C; Massow U
Urology; 2008 Oct; 72(4):803-7. PubMed ID: 18722655
[TBL] [Abstract][Full Text] [Related]
48. The relationship between subjective and objective assessments of sacral neuromodulation effectiveness in patients with urgency-frequency.
Peters KM; Killinger KA; Ibrahim IA; Villalba PS
Neurourol Urodyn; 2008; 27(8):775-8. PubMed ID: 18551573
[TBL] [Abstract][Full Text] [Related]
49. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.
Klutke CG; Burgio KL; Wyman JF; Guan Z; Sun F; Berriman S; Bavendam T
J Urol; 2009 Jun; 181(6):2599-607. PubMed ID: 19375110
[TBL] [Abstract][Full Text] [Related]
50. Tension-free vaginal tape and autologous rectus fascia pubovaginal sling for the treatment of urinary stress incontinence: a medium-term follow-up.
Sharifiaghdas F; Mortazavi N
Med Princ Pract; 2008; 17(3):209-14. PubMed ID: 18408389
[TBL] [Abstract][Full Text] [Related]
51. Transobturator tape (TOT): Two years follow-up.
Juma S; Brito CG
Neurourol Urodyn; 2007; 26(1):37-41. PubMed ID: 17083100
[TBL] [Abstract][Full Text] [Related]
52. Creation and testing of the Geriatric Self-Efficacy Index for Urinary Incontinence.
Tannenbaum C; Brouillette J; Korner-Bitensky N; Dumoulin C; Corcos J; Tu le M; Lemieux MC; Ouellet S; Valiquette L
J Am Geriatr Soc; 2008 Mar; 56(3):542-7. PubMed ID: 18179504
[TBL] [Abstract][Full Text] [Related]
53. The validity of prospective and retrospective global change criterion measures.
Schmitt J; Di Fabio RP
Arch Phys Med Rehabil; 2005 Dec; 86(12):2270-6. PubMed ID: 16344022
[TBL] [Abstract][Full Text] [Related]
54. Development and testing of a scale to measure self-efficacy for pelvic muscle exercises in women with urinary incontinence.
Broome BA
Urol Nurs; 1999 Dec; 19(4):258-68. PubMed ID: 10889770
[TBL] [Abstract][Full Text] [Related]
55. Validation of the Swedish version of the incontinence impact questionnaire and the urogenital distress inventory.
Franzén K; Johansson JE; Karlsson J; Nilsson K
Acta Obstet Gynecol Scand; 2013 May; 92(5):555-61. PubMed ID: 22686542
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of sacral neuromodulation for symptomatic treatment of refractory urinary urge incontinence.
Latini JM; Alipour M; Kreder KJ
Urology; 2006 Mar; 67(3):550-3; discussion 553-4. PubMed ID: 16527577
[TBL] [Abstract][Full Text] [Related]
57. Measuring the severity of stress urinary incontinence using the Incontinence Impact Questionnaire.
Handa VL; Massof RW
Neurourol Urodyn; 2004; 23(1):27-32. PubMed ID: 14694453
[TBL] [Abstract][Full Text] [Related]
58. Transurethral radiofrequency energy collagen micro-remodeling for the treatment of female stress urinary incontinence.
Appell RA; Juma S; Wells WG; Lenihan JP; Klimberg IW; Kanellos A; Reilley SF
Neurourol Urodyn; 2006; 25(4):331-6. PubMed ID: 16673379
[TBL] [Abstract][Full Text] [Related]
59. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
Choo MS; Doo CK; Lee KS
Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
[TBL] [Abstract][Full Text] [Related]
60. Comparison between reduction in 24-hour pad weight, International Consultation on Incontinence-Short Form (ICIQ-SF) score, International Prostate Symptom Score (IPSS), and Post-Operative Patient Global Impression of Improvement (PGI-I) score in patient evaluation after male perineal sling.
Twiss CO; Fischer MC; Nitti VW
Neurourol Urodyn; 2007; 26(1):8-13. PubMed ID: 17016797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
